Pertuzumab (Perjeta®)

This is a monoclonal antibody drug—administered through an IV—that targets cancer cells with an increased amount of HER2 protein. It’s given with trastuzumab (Herceptin®) and chemotherapy to treat HER2-positive metastatic breast cancer or HER2-positive cancer that is inflammatory, locally advanced, or early stage with a high chance of returning.